A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease

Inclusion criteria

• Participants who are overtly healthy as determined by medical evaluation, including medical history and physical examination.
• Have mild memory complaints or a diagnosis of mild cognitive impairment.
• Have undergone genotyping for apolipoprotein E (APOE) and are willing to make results available to the investigator.
• Montreal Cognitive Assessment (MoCA) score of greater than or equal to 22 and less than or equal to 28.

Exclusion criteria

• Have any medical condition that, in the opinion of the investigator, would be a contraindication to participation in the study.
• Have an existing diagnosis of AD or other dementia.
• Have contradictions to or an allergy to the ophthalmic dilating agents.
• Have known diagnosis of severe glaucoma or severe cataracts; have a significant refractive error (more than 12 diopters [D] of spherical equivalent refraction); or have any ocular media opacity that prevents imaging of the retina (that is, severe cataract). Note: mild to moderate cataracts or vision correction with glasses or contact lenses are not exclusion criteria.
• Current or previous treatment with anti-amyloid medications.
• Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.